At a glance
- Originator Pfizer
- Class Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 25 Oct 2000 Profile reviewed but no significant changes made
- 22 Jan 1997 No-Development-Reported for Cognition disorders in USA (Unknown route)